KIMBERLY BUZZELLI: Open Payments
NPI 1063794212 · LYNCHBURG, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,942 in 116 payments from 10 companies in 2025. Trend: 2023 $559 · 2024 $1,235 · 2025 $1,942
Food & beverage: $1,942
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 49 | $520 |
| Neurocrine BioSciences, Inc. | 25 | $388 |
| Otsuka America Pharmaceutical, Inc. | 11 | $283 |
| Lundbeck LLC | 8 | $174 |
| Janssen Pharmaceuticals, Inc | 6 | $172 |
| Vanda Pharmaceuticals Inc. | 6 | $162 |
| E.R. Squibb & Sons, L.L.C. | 3 | $107 |
| ABBVIE INC. | 4 | $59 |
| Alkermes, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 1 | $31 |
Products named: CAPLYTA, INGREZZA, ABILIFY MAINTENA, REXULTI, INVEGA SUSTENNA, COBENFY, HETLIOZ, FANAPT.
Industry payments across VA — which companies pay providers there.
